Non-Islet Cell Tumor Hypoglycemia (Nicth) Associated With Sarcoma, Case Report Publisher Pubmed



Jannatalipour A^{1, 6} ; Panahi N^{2, 6} ; Pejman Sani M^{1, 6} ; Ghaemi O³ ; Kheirandish M¹ ; Alipour N¹ ; Zarinkolah A¹ ; Jawhari M⁴ ; Rasuli B⁴ ; Mohajeritehrani MR¹ ; Aghaei Meybodi HR^{1, 5} ; Soltani A^{1, 5} Show Affiliations
Source: BMC Endocrine Disorders Published:2025

Abstract

Non-islet cell tumor hypoglycemia (NICTH) is a rare paraneoplastic syndrome caused by the secretion of high molecular weight insulin-like growth factor II (IGF-II) from tumors, particularly those of mesenchymal and epithelial origin. This case report describes a 71-year-old male with pelvic sarcoma who presented with severe hypoglycemia, with blood glucose levels dropping below 40 mg/dL and exhibiting neuroglycopenic symptoms. The diagnosis of NICTH was confirmed through biochemical analysis showing hypoinsulinemic hypoglycemia alongside low C-peptide and IGF-1 levels. Initial management with dextrose infusions and glucocorticoids proved ineffective until recombinant human growth hormone (rhGH) therapy was initiated, resulting in a decreased requirement for dextrose. Following angioembolization of the tumor, the patient’s blood glucose levels stabilized sufficiently to allow for the complete cessation of dextrose administration. This case highlights the critical role of rhGH in reducing dextrose dependency and the effectiveness of angioembolization in managing NICTH when surgical options are limited. © The Author(s) 2025.